Pharmacokinetics of the Dual Melatonin Receptor Agonist Tasimelteon in Subjects With Hepatic or Renal Impairment

Journal of Clinical Pharmacology - United States
doi 10.1002/jcph.440
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Wiley

Related search

Effect of Hepatic or Renal Impairment on the Pharmacokinetics of Evacetrapib

European Journal of Clinical Pharmacology
MedicinePharmacology
2016English

The Pharmacokinetics and Safety of Darapladib in Subjects With Severe Renal Impairment

British Journal of Clinical Pharmacology
Pharmacology
2015English

Optimization of Dalbavancin in Patients With Hepatic or Renal Impairment

Pharmacology & Pharmacy
2020English

Single-Dose Pharmacokinetics and Safety of Daclatasvir in Subjects With Renal Function Impairment

Antiviral Therapy
Infectious DiseasesPharmacology
2015English

Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects With Severe Renal Impairment

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2016English

Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects With Renal Impairment

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2018English

Single-Dose, Open-Label Study of the Differences in Pharmacokinetics of Colchicine in Subjects With Renal Impairment, Including End-Stage Renal Disease

Clinical Drug Investigation
MedicinePharmacology
2014English

The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus

Journal of Clinical Pharmacology
Pharmacology
2017English

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib

Journal of Clinical Pharmacology
Pharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy